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225 Abstract 
26 Context and objective.  Incidence of prostate cancer (PC) is increasing, but androgen 
27 deprivation therapy (ADT) and other therapies are substantially improving survival. In this 
28 context, careful consideration of skeletal health is required to reduce the risk of treatment-
29 related fragility fractures and their associated morbidity and mortality. This risk is currently 
30 not well-managed. ADT causes significant loss of bone mineral density (BMD). In the 
31 metastatic setting, systemic treatments (eg chemotherapy, abiraterone, enzalutamide) are 
32 used alongside ADT and may require concomitant glucocorticoids.  Both ADT and 
33 glucocorticoids pose significant challenges to skeletal health in a population of patients 
34 already likely to have ongoing age-related bone loss and/or comorbid conditions.  Current 
35 PC guidelines lack specific recommendations for optimising bone health. This guidance 
36 presents evidence for assessment and management of bone health in this population, with 
37 specific recommendations for clinical practitioners in day-to-day PC management. 
38 Methods.  Structured meetings of key opinion leaders were integrated with a systematic 
39 literature review.  Input and endorsement was sought from patients, nursing 
40 representatives and specialist societies. 
41 Summary of guidance.  All men starting or continuing long-term ADT should receive lifestyle 
42 advice regarding bone health. Calcium/vitamin D supplementation should be offered if 
43 required. Fracture risk should be calculated (using the FRAX® tool), with BMD assessment 
44 included where feasible.  BMD should always be assessed where fracture risk calculated 
45 using FRAX® alone is close to the intervention threshold.  Intervention should be provided if 
46 indicated by local or national guidelines e.g. UK National Osteoporosis Guideline Group 
47 (NOGG) thresholds.  Men requiring bone protection therapy should be further assessed (e.g. 
48 renal function), with referral to specialist centres if available and offered appropriate 
349 treatment to reduce fracture risk.  Those near to, but below an intervention threshold, and 
50 patients going on to additional systemic therapies (particularly those requiring 
51 glucocorticoids), should have FRAX® (including BMD) repeated after 12-18 months.  
52
53 Patient Summary
54 Modern treatments for prostate cancer have led to significant improvements in survival and 
55 quality of life. However, some of these treatments may lead to weakening of patients 
56 bones with risk of fracture and it is therefore important to monitor patients bone health 
57 and provide bone protection where needed.  This paper provides specific guidance to 
58 clinical teams, based on the most recent research evidence, to ensure optimal bone health 
59 in their patients. 
460 1. Introduction
61 Bone health is emerging as one of the most important considerations for men receiving 
62 treatment for prostate cancer (PC). Projected to be the commonest cancer by 2030, 1 in 8 
63 men will receive a diagnosis of PC in their lifetime. There are more than 400,000 new cases 
64 of PC in Europe each year. Despite the fact that PC is the second leading cause of cancer-
65 related mortality in men[1], survival rates have improved considerably over the past four 
66 decades as a result of both earlier diagnosis and newer therapies (current 5-year survival is 
67 85% in all patients, compared with 71% in 1980)[2].  
68 As a result, many patients with PC now live with their disease for many years, and 
69 consideration of the long-term consequences of treatment is of increasing importance.  
70 Men with PC are not routinely referred to bone specialists for optimisation of their bone 
71 health, despite the fact that cancer treatment induced bone loss (CTIBL) and the resulting 
72 increased risks of fragility fractures (often requiring hospitalisation) represent substantial 
73 problems for patients and healthcare systems[3], in addition to those posed by pathological 
74 fractures in men with metastatic bone involvement[4]. New PC therapies, whilst improving 
75 survival, often add to this risk [5].  There is an urgent need for increased focus on these 
76 issues. This guidance aims to provide non-bone specialists with evidence-based 
77 recommendations to support the assessment and management of bone health in men 
78 receiving PC treatment. 
79 2. Methodology
80 Expert group and specialist society involvement
81  This guidance was developed by a group of key opinion leaders in the management of PC 
82 and bone disorders.  The group included medical and clinical oncologists, urologists, 
583 endocrinologists, rheumatologists, metabolic bone disease specialists, general practitioners 
84 and uro-oncology nurse specialists, with input from patient representatives. 
85 Input/endorsement was also sought from specialist societies (see acknowledgements). 
86 Current guidelines
87 Current national and international guidelines lack detailed, recommendations developed 
88 specifically for managing CTIBL in men receiving treatment for PC. The UK National Institute 
89 for Health and Care Excellence (NICE) Clinical Guideline makes only general 
90 recommendations; that fracture risk is considered for all men receiving ADT and that 
91 treatment is offered to all those with osteoporosis[6]. Joint European Association of 
92 Urology, European Society for Radiotherapy and Oncology (ESTRO) and International Society 
93 for Geriatric Oncology (SIOG) PC guidelines suggest that BMD assessment is undertaken 
94 prior to the initiation of long-term ADT, and that the FRAX® tool should be used to estimate 
95 individual fracture risk[7] . Recent ASCO guidance is based on endorsement of a 2017 
96 Cancer Care Ontario Programme [8] and Guidance from the National Comprehensive Cancer 
97 Network (NCCN) recommends screening and treatment for osteoporosis according to 
98 guidelines for the general population from the National Osteoporosis Foundation [9].  
99 There is no current guidance as to the intervention thresholds that should be used to initiate 
100 treatment, or the most appropriate pharmacological therapy.  It is often unclear who should 
101 have overall responsibility for managing bone health in PC patients, many of whom will be 
102 managed in a multi-disciplinary setting across both primary and secondary care. 
103 Definition of scope
104 The scope of the guidance was defined as follows: 
6105  To address the need for specific guidance for the management of CTIBL in PC 
106 (including intervention thresholds) in a European setting
107  To summarise the evidence supporting the management of bone health during PC 
108 treatment for non-bone specialists (including general practitioners, urologists, 
109 oncologists and specialist nurses) involved in the care of patients with PC at risk of 
110 CTIBL.
111  Using the UK as an exemplar, to sit the PC guidance alongside the NICE-accredited 
112 National Osteoporosis Guidance Group Clinical Guideline (2017) for the prevention 
113 and treatment of osteoporosis and the NICE guidance for the diagnosis and 
114 management of prostate cancer (NICE Clinical Guideline 175).
115 Search strategy and selection of evidence
116 A literature search was undertaken using PubMed and Ovid MEDLINE databases for relevant 
117 peer-reviewed articles published in English between January 2000 and July 2019. 
118 Randomised controlled trials, observational studies and meta-analyses were included. 
119 Search terms included prostate cancer, prostate carcinoma and prostate adenocarcinoma, 
120 and were mapped to the following subject headings for bone; bone health, bone density, 
121 bone mineral density, osteoporosis, osteopenia, bone turnover markers, bone biomarkers, 
122 fracture, skeletal related event, bisphosphonates, denosumab and exercise. For ADT, 
123 prostate cancer was used to search in combination with ADT, androgen deprivation therapy, 
124 androgen suppression, hormone therapy, GnRH agonist, luteinising hormone releasing 
125 hormone antagonist, and antiandrogens. 
126 Abstracts were screened for relevance by at least two members of the expert reference 
127 group, with any disagreement resolved by consensus after discussion.
7128 3. Prostate cancer and bone loss
129 Androgen deprivation therapy (ADT)
130 ADT is offered to men with PC in several different clinical settings, including: men who 
131 present with or progress to metastatic disease (continuous ADT); men who receive radical 
132 radiotherapy for localised or locally advanced disease (temporary ADT); and men who 
133 progress during a period of watchful waiting who are not fit for radical treatment (palliative 
134 continuous ADT). These indications are based upon clear evidence from large randomised 
135 clinical trials[10-13].  ADT may also be administered intermittently [14].
136 ADT is most commonly achieved by the administration of luteinising hormone releasing 
137 hormone (LHRH) agonists (such as goserelin and leuprorelin) and LHRH antagonists (such as 
138 degarelix). ADT causes a rapid and substantial reduction in circulating androgens and 
139 oestrogens, disrupting bone remodelling balance, stimulating osteoclast activity, decreasing 
140 osteoclast apoptosis, and increasing apoptosis of osteoblasts, all of which lead to net bone 
141 loss[15]. 
142 Even before ADT is initiated, PC patients may have lower baseline BMD than age-matched 
143 controls[16]. Prospective studies found that loss of BMD is most rapid during the first year 
144 of ADT (5-10% BMD loss)[17,18] and is greater than both normal age-related bone loss (0.5-
145 1.0% per annum) and bone loss during menopause.  Bone loss, as well as disruption to bone 
146 microarchitecture[19] continues throughout the duration of ADT and ongoing CTIBL in men 
147 with PC is superimposed upon normal age-related bone loss (more than half of men 
148 diagnosed with PC are aged over 70 years).  It is likely that older men will also have risk 
149 factors for fragility fracture other than ADT, such as risk of falls and comorbid conditions. 
8150 ADT also affects body composition. Adiposity is substantially increased along with a 
151 decrease in lean body mass within 3-12 months of ADT initiation[20]. ADT-induced 
152 sarcopenia, defined as a progressive impairment of muscle function due to loss of skeletal 
153 muscle mass, increases the risk of falls, fractures and consequent loss of function or 
154 independence[18].  
155 Chemotherapy
156 The STAMPEDE and CHAARTED trials have demonstrated survival benefit when 
157 chemotherapy is given upfront alongside ADT in men with metastatic hormone-sensitive 
158 PC[21,22]. Men in this situation who are fit enough are currently offered six cycles of 
159 docetaxel. In the STAMPEDE study, glucocorticoids were given alongside each cycle of 
160 docetaxel as pre-medication (dexamethasone) and as a daily dose of prednisolone (10mg 
161 per day) throughout the treatment period of up to 18 weeks. In many (but not all) centres, 
162 this glucocorticoid regime is now adopted as standard of care, further challenging bone 
163 health.
164 Other systemic therapies
165 Abiraterone acetate is a selective androgen synthesis inhibitor which blocks androgen 
166 production in the testes, adrenals and prostate tumour tissue. It is recommended for use in 
167 men with metastatic castration resistant prostate cancer (mCRPC)[23] and has also been 
168 found to improve survival in men with newly diagnosed hormone-sensitive metastatic PC 
169 (compared to ADT alone)[24,25]. It is currently approved in the USA, and recommended by 
170 ESMO and EAU for use in this setting[26]. As abiraterone also blocks the production of 
171 glucocorticoids, prednisolone (usual dose 10mg/day) is given together with abiraterone, and 
172 may further challenge bone health. 
9173 Enzalutamide is an oral androgen receptor inhibitor that is currently used in men with 
174 mCRPC[27], which does not require concomitant glucocorticoids. Enzalutamide may also 
175 have a role in the management of non-metastatic CRPC[28] and also in metastatic castrate 
176 sensitive disease[29]. Other anti-androgen agents are in development or newly-approved 
177 (eg darolutamide[30] and apalutamide[31]) with currently unknown effects on fracture rate 
178 and assessment of bone health will be of growing and continuing importance. Radium-223 
179 monotherapy, given IV, is widely used for treatment of mCRPC which has metastasised only 
180 to the skeleton, following trials which showed an overall survival benefit of 3.6 months [32]  
181 and a reduced risk of symptomatic skeletal related events (SSREs)[33]However, in the 
182 REASURE trial, new fractures were commonly seen on imaging in men with mCRPC during 
183 and after treatment with Ra-223 monotherapy[34] and, when radium-223 is used in 
184 combination with other agents, increased fracture risk has been observed as reported in a 
185 combination study where the addition of radium-223 to abiraterone acetate plus prednisone 
186 or prednisolone did not improve SSRE-free survival in patients with castration-resistant 
187 prostate cancer and bone metastases, and was associated with an increased frequency of 
188 bone fractures compared with placebo.[5]
189  Interim data from the ongoing EORTC1333/PEACEIII study, showed that addition of radium-
190 223 to enzalutamide increased the 1-year cumulative fracture rate  from 12.4% (already 
191 significant with enzalutamide alone)  to 27.4%, but remarkably no fractures occurred when 
192 patients started treatment with a bone-protecting agent at least 6 weeks before radium-223 
193 administration[35]. These are interim data, but they dramatically illustrate the importance 
194 of considering bone protection and following appropriate guidance. When full data become 
195 available, they may well justify all such mCRPC patients routinely receiving bone protection.  
196 In patients with bone metastases from CRPC at high risk for clinically significant SREs, ESMO 
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197 guidelines recommend denosumab or zoledronate at doses higher than those required for 
198 protection against CTIBL alone. 
199 4. Glucocorticoids and bone loss
200 The long-term use of glucocorticoids is the commonest cause of iatrogenic osteoporosis and 
201 one of the commonest causes of secondary osteoporosis. As a consequence of increased 
202 bone resorption, decreased formation and interruption of regulatory pathways, there is an 
203 early and rapid loss of BMD and bone quality. The risk of hip and vertebral fractures 
204 increases up to 7- and 17- fold respectively when doses equivalent to 10-12mg prednisolone 
205 are given for more than 3 months[36]. There is a need for further studies to investigate the 
206 impact of the combination of docetaxel and glucocorticoids on bone health and risk of 
207 fracture in men with PC. 
208 5. Osteoporosis
209 Osteoporosis is a progressive systemic skeletal disorder, characterised by low bone mass 
210 and microarchitectural deterioration of bone tissue, with a consequent increase in bone 
211 fragility and susceptibility to fracture[37]. Its prevalence increases with age, due to both 
212 age-related loss of BMD (0.5%-1.0% per year) and the presence of factors that accelerate 
213 bone loss, such as the menopause, lifestyle factors, presence of comorbid conditions and 
214 use of medications affecting bone. 
215 The World Health Organization (WHO) definition of osteoporosis, is based upon BMD. Using 
216 dual energy X-ray absorptiometry (DXA), a BMD T-score of 2.5 SD or more below the mean 
217 value for young healthy adults is diagnostic of osteoporosis[38].  The proximal femur (total 
218 hip or femoral neck) is an important site to assess due to its higher predictive risk for hip 
219 fracture.  Measurement of lumbar spine (LS) BMD should also be considered in all patients, 
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220 though the presence of degenerative changes, vascular calcification and fractures may 
221 affect interpretation of the result. In Europe, there are 22 million women and 5.5 million 
222 men living with osteoporosis, which is responsible for 3.5 million fragility fractures per year. 
223 The economic burden of both incident and prior fragility fractures has been estimated at 
224 37 billion[39].  
225 Fragility fractures arise as a consequence of low energy mechanical forces that would not 
226 ordinarily cause fracture (equivalent to a fall from standing height or less), and most 
227 commonly affect the proximal femur (hip), vertebrae and distal radius[40]. Hip fractures, in 
228 particular, pose a considerable challenge to health and social care provision. Significant 
229 morbidity arises from the consequent pain, disability and loss of independence, with over 
230 50% of patients unable to live independently, and only 30% recovering fully. The association 
231 between hip fracture and mortality is well established, with around one third of patients 
232 dying within 12 months[41]. Importantly, mortality following hip fracture is significantly 
233 higher in men[42]. 
234 Several other factors that are BMD-independent may also contribute to fracture risk 
235 including; age, sex, increased risk of falls, previous fracture, family history of fracture, and 
236 other lifestyle factors. Fracture risk assessment tools such as FRAX® and QFracture have 
237 been developed, to integrate these variables with other information in order to better 
238 determine the risk of fracture. 
239 A range of bone turnover markers (BTMs), mostly related to collagen metabolism, can be 
240 measured in urine or serum, to indicate the status of bone formation and bone resorption. 
241 While not used widely in clinical practice, they may be particularly useful in monitoring the 
242 response of bone turnover to pharmacological treatments[43].
12
243 6. Management of CTIBL in prostate cancer
244 Patient and clinician education
245 Evidence suggests that men with PC receiving ADT often lack basic osteoporosis knowledge 
246 and do not actively seek to take measures to optimise their bone health[44]. Provision of 
247 individualised, patient-centred information can improve knowledge and engagement with 
248 appropriate lifestyle modifications. Published surveys of urologists and oncologists have 
249 found that clinicians lack confidence in providing self-management advice to patients to 
250 optimise bone health, and do not feel able to effectively manage men who are identified as 
251 having abnormal BMD[45,46]. We recommend this is addressed by clinicians following 
252 Figures 3 and 4 of this guidance which will be made available as a simple downloadable 
253 guide. 
254 Lifestyle factors
255 Both smoking and excessive alcohol intake are associated with lower BMD in men with PC, 
256 and should be avoided[47]. It has been demonstrated that exercise improves muscular 
257 strength, cardiorespiratory fitness, lean body mass, fatigue, and quality of life in men 
258 receiving treatment for PC[48]. NICE Clinical Guideline 131 [49] for PC recommends that all 
259 men starting or having ADT should be offered supervised resistance and aerobic exercise at 
260 least twice a week for 12 weeks.  Further advice is provided by many organisations, 
261 including the Royal Osteoporosis Society in the UK [50], the European Society of Medical 
262 Oncology  ( ESMO) [51] and a compendium of EU-specific reports [52].
263 The role of calcium and vitamin D 
264 Daily calcium intake (DCI) is inadequate in the majority of older men with PC[53]. The NOGG 
265 recommends a DCI of 700-1200mg, if possible through dietary intake with supplements if 
13
266 needed.  DCI may be calculated using an online tool 
267 (http://www.cgem.ed.ac.uk/research/rheumatological/calcium-calculator). 
268 Optimal bone health requires vitamin D (serum 25-hydroxyvitamin D 25-OHD) levels of at 
269 least 50 nmol/L, and levels below 30 nmol/L significantly increase the likelihood of bone 
270 disease[54]. Vitamin D deficiency affects more than a quarter of older men, with up to three 
271 quarters found to have insufficiency (25-50 nmol/L).  NOGG recommends vitamin D 
272 supplementation with 800IU daily in all men aged over 50 at increased risk of fracture[55]. 
273
274 Bone protective agents
275 In randomised studies (Table 1)[56-69], bisphosphonates including pamidronate, 
276 neridronate, risedronate, zoledronate and alendronate have been shown to be effective in 
277 the prevention of BMD loss associated with ADT at the lumbar spine (LS), femoral neck and 
278 total hip, with accompanying significant reduction in BTMs. 
279 However, bisphosphonate studies to date have had important limitations including small 
280 patient numbers, heterogeneous populations, variation in type and frequency of 
281 bisphosphonate administration, and varying follow-up schedules. Importantly, no study has 
282 been sufficiently powered to detect differences in fracture incidence, though a meta-
283 analysis of 15 randomised studies including 2,634 patients receiving ADT showed that 
284 treatment with bisphosphonates prevented fracture (RR 0.8, 95% CI 0.69 to 0.94, 
285 p=0.005)[70].  Most studies that compared zoledronic acid with placebo used a 4mg dose 
286 administered 3-monthly, a higher dose than the 5mg infused annually for the treatment of 
287 osteoporosis.  It is unlikely that large, prospective, randomised bisphosphonate trials for 
288 prevention of bone loss and reduction of fracture rate in men receiving ADT will be carried 
289 out and no bisphosphonate is currently approved for this specific purpose. However, it 
14
290 seems reasonable to use bisphosphonates in men with PC under the same rationale as they 
291 are used to manage other forms of osteoporotic bone loss.  
292 Larger randomised studies have been performed for denosumab in men receiving ADT 
293 (details in Table 1).  In a placebo-controlled  study, denosumab significantly increased BMD 
294 and reduced   incidence of new vertebral fractures[66].  In a randomised study in Italy, 
295 France and Switzerland comparing denosumab with alendronate[67], denosumab was 
296 superior in terms of improved LS BMD after 2 years. Although no significant difference was 
297 observed in fracture rate,  on the basis of these results, denosumab has been authorised by 
298 the European Medicines Authority for use in the prevention of CTIBL associated with ADT.  
299 However, given that no significant difference if fracture rate has been observed,  it should 
300 be noted that there are differences in both cost and side-effect profiles between 
301 denosumab and alendronate (and other bisphosphonates) and, as with all bone-targeted 
302 agents, the choice of agent will depend on patient need and local practice.
303 Bisphosphonates and denosumab are associated with similar adverse effects, the most 
304 serious of which is osteonecrosis of the jaw (ONJ). Studies of denosumab in both metastatic 
305 PC and non-metastatic CRPC reported ONJ incidence of O 5%[71,72]. Similarly, the frequency 
306 of ONJ with bisphosphonate use in men with PC is 1-2%[72]. Importantly, these are based 
307 on doses used in metastatic bone disease (4mg zoledronic acid or 120mg denosumab every 
308 4 weeks). With lower doses, the incidence in osteoporosis patients is substantially lower, 
309 estimated at between 0.001% and 0.01%[73].  Both denosumab and bisphosphonates are 
310 associated with an increased risk of hypocalcaemia, but when denosumab was given twice 
311 yearly to men with PC on ADT, the incidence of hypocalcaemia was less than 1%[66].
312 Other pharmacological treatments for osteoporosis (including the selective oestrogen 
313 receptor modulators raloxifene and toremifene) are not currently recommended to prevent 
15
314 bone loss in PC patients receiving ADT. Teriparatide (recombinant PTH) is contraindicated in 
315 patients with metastatic bone disease and in those who have received prior radiotherapy.
316 Where patients with metastatic prostate cancer are already receiving anti-resorptive 
317 therapy for the management of their metastatic disease (usually at higher doses than 
318 required for prevention of osteoporosis), there is clearly no benefit from further bone 
319 health monitoring, as patients will already be receiving the appropriate therapy to 
320 prevent/treat bone loss. 
321
322 7. Fracture risk assessment and interventions
323 Risk assessment tools are available to determine the risk of fragility fracture for individual 
324 patients. Additional clinical risk factors contribute to fracture risk, at least partially 
325 independently of BMD (indeed most fractures occur in individuals subsequently found to 
326 have non-osteoporotic BMD). The two most frequently used tools are the Fracture Risk 
327 Assessment Tool (FRAX® available at https://www.sheffield.ac.uk/FRAX), which calculates 
328 10 year probability of fracture and, QFracture (https://qfracture.org) in the UK only, which 
329 can calculate 1-10 year incidence of fracture.  Both tools estimate the risk of hip fracture 
330 alone and other major osteoporotic fractures (hip, clinical spine, wrist or humerus). Unlike 
331 QFracture, FRAX® may be used with or without BMD. In contrast to FRAX®, there are 
332 currently no published intervention thresholds using the QFracture tool. Neither has been 
333 specifically developed for use in men with PC.
334 FRAX®
335 FRAX® is based on primary data from 12 prospectively studied population-based 
336 international cohorts, comprising more than 60,000 individuals and 5,000 incident fractures, 
16
337 with subsequent external validation in cohorts comprising 230,486 individuals. Although 
338 men comprised only 25% of the original FRAX® cohorts,  current evidence suggests that the 
339 risk is the same in both sexes and the tool has been shown to be of predictive value in both 
340 male and mixed gender cohorts[74]. 
341 FRAX® does not require specialist knowledge and can be performed in general practice or 
342 outpatient settings.  It incorporates a relatively small number of clinical risk factors (Figure 
343 1). Anticancer treatments are not currently included as a specific risk factor.  FRAX® 
344 computes fracture probability taking both the risk of fracture and risk of death into account, 
345 important because some risk factors affect both. FRAX® is used in an increasing number of 
346 guidelines worldwide. In addition to providing an estimate of risk, the FRAX® website in 
347 some country models has a link to national guidance for the management of osteoporosis 
348 (such as the UK National Osteoporosis Guideline Group in the UK).  
349 FRAX has recently been shown to be predictive of falls in elderly men[75]. This is particularly 
350 significant in older men receiving ADT, which alters body composition. As well as increasing 
351 the risk of falls, sarcopenia also decreases rehabilitation potential in the post-fall setting[76].  
352 FRAX® and ADT
353 The inclusion of ADT as a new, specific risk variable within FRAX® would require sufficient 
354 evidence that ADT is associated with fracture risk independently of the risk variables already 
355 included, particularly BMD.  Current evidence suggests that this may not be the case[77,78].  
356 A conservative assumption, therefore, would be that the modification of fracture risk by 
357 ADT is captured almost completely by its impact on BMD.  The secondary osteoporosis 
358 variable in FRAX® already serves this function and so should be ticked when patients receive 
359 ADT. This variable contains a number of risk factors that have been shown to be associated 
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360 with fracture risk (RR 1.3-1.7) but with little or no evidence that this risk is truly independent 
361 of BMD.  Thus, if and when BMD is entered to the calculation, no further weight is accorded 
362 to the presence of this risk factor.  As for any clinical prediction tool, interpretation should 
363 be tempered by additional information of clinical significance; such as a high falls risk, 
364 multiple prior fractures, immobility and severe rheumatoid arthritis. 
365 In addition to ADT, men with newly diagnosed metastatic prostate cancer may also receive 
366 additional systemic therapies, which are given with concurrent glucocorticoids. Docetaxel 
367 chemotherapy involves daily prednisolone and pre-treatment dexamethasone, for up to 18 
368 weeks.  Abiraterone acetate may also be given along with a daily dose of prednisolone for 
369 up to 2 years. All men undergoing prolonged periods of exposure to medium/high doses of 
370 glucocorticoids have a greater risk of fracture, which is reflected in its inclusion in the FRAX® 
371 risk factors. 
372 Intervention thresholds
373 Approaches used to set intervention thresholds[79,80] depend on local factors such as 
374 reimbursement policies, health economic assessment, willingness to pay for health care in 
375 osteoporosis and access to DXA.  Most recommendations for intervention thresholds in 
376 osteoporosis are based on postmenopausal osteoporosis where there is an established 
377 evidence base, but NOGG has included the management of male osteoporosis in their most 
378 recent guidance[55]. Since it would be difficult to justify a different (i.e. lower) intervention 
379 threshold in men, it is logical to apply the same thresholds in men with PC.  Thus, men with 
380 probabilities at or above the upper threshold (Figure 2) should be offered treatment.   
381 As current evidence suggests that fracture risk in ADT users is BMD-dependent, it is 
382 reasonable to suggest that BMD should be included in the risk calculation by FRAX® for all 
383 PC patients, wherever this is feasible.  Where access to BMD is limited, FRAX® should be 
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384 performed and BMD measurements targeted to those men with FRAX® probabilities, 
385 calculated without BMD (but selecting the secondary osteoporosis box to recognise ADT), 
386 lying close to the intervention threshold (for example, the amber area on the chart available 
387 at https://www.sheffield.ac.uk/NOGG/result-nobmd.html?).  
388 Further assessment prior to treatment
389 Men with a previous fracture and/or who are found to be osteoporotic should have further 
390 investigations to exclude other causes of secondary osteoporosis, as treatment of the latter 
391 (e.g. malabsorption or liver disease) forms part of overall management.  This may be best 
392 achieved by referral to appropriate services (metabolic bone/rheumatology/endocrinology). 
393 Dosing regimens
394 NOGG recommends oral bisphosphonates such as alendronate (10mg daily) or risedronate 
395 (5mg daily) for osteoporosis in men, reflecting the licensed doses. In clinical practice, 
396 however, the majority of men receive once weekly oral bisphosphonates (alendronic acid 
397 70mg or risedronate sodium 35mg) as used in women with postmenopausal osteoporosis. 
398 Oral therapy can often be initiated by the patients GP following assessment of fracture risk.  
399 Where oral therapy is not feasible or tolerated, intravenous zoledronic acid may be used 
400 (5mg once yearly), or denosumab can be given subcutaneously at a dose of 60 mg once 
401 every 6 months.
402 Reassessment of fracture risk
403 Fracture risk reassessment should be undertaken when there is a change in systemic 
404 therapy or a change in risk factor profile (e.g. commencing glucocorticoids, incident fracture, 
405 development of other cause of secondary osteoporosis etc).  In men on ADT whose fracture 
406 risk lies below but close to the intervention threshold, a FRAX reassessment (including a 
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407 repeat BMD) should be undertaken after 12-18 months.  All men who have been on ADT for 
408 5 years should be reassessed even if they were not deemed at risk on baseline FRAX®.
409 In those on bone protective therapy, reassessment should be undertaken in 3 years for 
410 those receiving intravenous zoledronate annually, or 5 years for oral bisphosphonate use.  
411 Denosumab use should also be reviewed at 5 years but not discontinued without review in a 
412 specialist bone service.
413 8. Conclusions
414 Maintenance of bone health is increasingly important in patients with PC where, even in 
415 advanced disease, survival is now typically several years. The range and numbers of lines of 
416 treatment men receive, especially in the advanced setting, is increasing and many have 
417 impacts on the skeleton.  It is critical to embed consideration of bone health and its 
418 optimisation throughout the patient journey. 
419 9. Recommendations
420 The clinical guidance summarised in Figures 3 and 4 should be followed for all men 
421 commencing ADT and for all men currently on ADT who have not had previous assessment 
422 of fracture risk. It is important that all care pathways, although they may vary locally, should 
423 identify at an early stage who in the care pathway carries responsibility for bone health 
424 monitoring and treatment.  We recommend that these guidelines should be available as a 
425 quick reference guide, including a brief summary and algorithm, as an electronic download 
426 for use in routine practice. 
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676 Legends to Figures
677 Figure 1:  The UK FRAX® tool.  
678 Screenshot showing a FRAX®calculation of major fracture and hip fracture probability in a 
679 man aged 70 years with secondary osteoporosis (e.g. prostate cancer on ADT). Note that, 
680 because there is no BMD measurement included, the secondary osteoporosis factor has 
681 been checked as 'Yes' in recognition of the patient being on ADT.  If a BMD measurement 
682 was included, the FRAX® risk calculation would take no account of whether the secondary 
683 osteoporosis box is checked or not as the BMD takes precedence.
684 Figure 2: NOGG intervention thresholds. 
685 The thresholds depicted by the lines between the green and red areas above are the 10-
686 year probabilities of a major osteoporotic fracture (left graph) or hip fracture (right graph) in 
687 women with a previous fracture. Applying the same criteria to men with PC, treatment 
688 should be strongly considered in those with fracture probabilities at or above the threshold.
689 Figure 3: Algorithm for assessment of bone health in prostate cancer patients receiving 
690 ADT
691 Note regarding patients with mCRPC:  Around 80% mCRPC patients develop bone 
692 metastases.  In patients with bone metastases from CRPC at high risk for clinically significant 
693 SREs, ESMO guidelines recommend denosumab or zoledronate at doses higher than those 
694 required for protection against CTIBL alone. However, where mCRPC patients do not already 
695 receive bone protection for prevention of metastatic morbidity, in view of emerging data 
696 referred to in Section 3, it is strongly recommended that all such patients should be 
697 considered for bone protection to prevent osteoporotic fragility fractures.
698 Figure 4:  Guidance for clinicians
32
699 The following guidance is given for management of bone health in patients with prostate 
700 cancer starting ADT or for patients already receiving ADT who have not previously had a 
701 bone health assessment.
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715 Highlights
716  Bone health should be prioritised when men with prostate cancer start long-term 
717 ADT.  
718  Assessment by FRAX (± bone mineral density) identifies those at highest risk of 
719 fracture. 
720  Treatment can minimise skeletal complications and reduce morbidity and mortality.
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All men starting or already receiving long-term ADT for Prostate Cancer should:
1. Be provided with individualised and patient-centred information, including appropriate lifestyle advice 
regarding optimisation of bone health.
2. Be referred to a supervised resistance and aerobic exercise programme of at least 12 weeks duration (in 
accordance with UK NICE guidelines) or as recommended in specific country guidelines.
3. Have daily calcium intake calculated to identify need for supplementation (using a tool such as the Edinburgh 
calculator http://www.cgem.ed.ac.uk/research/rheumatological/calcium-calculator).
4. Achieve or maintain adequate daily calcium (700- 1200mg) and vitamin D (800 IU) intake through dietary intake, 
sunlight exposure, and supplementation if needed.
5. Have their fracture risk assessed using FRAX® to determine 10-year probability of major osteoporotic and hip 
fracture https://www.sheffield.ac.uk/FRAX/tool.jsp  ensuring that ADT is included as a secondary osteoporosis 
risk factor, and that glucocorticoid use required with any planned systemic cancer therapy is included in FRAX as 
a risk factor.  
6. Wherever possible, undergo DXA to assess BMD, alongside FRAX, when ADT is commenced. BMD should always 
be measured when FRAX probabilities, calculated without BMD (but selecting the FRAX secondary osteoporosis 
box to recognise ADT), lie close to the intervention threshold (for example, the amber area on the chart 
available at https://www.sheffield.ac.uk/NOGG/result-nobmd.html?).  
7. Those found to have a high probability of fracture should be offered appropriate pharmacological treatment. 
Choice of therapy should follow current NOGG guidance https://www.sheffield.ac.uk/NOGG/index.html: oral 
alendronate and risedronate,  denosumab (subcutaneous) or zoledronic acid (intravenous) or as recommended 
in specific country guidelines.
8. Those close to but below the intervention threshold should have their FRAX/BMD reassessed after 12-18 
months of ADT or at a change in systemic therapy. FRAX/BMD should be reassessed in patients who have been 
on ADT for 5 years. 
9. Be investigated for other causes of secondary osteoporosis if BMD is within the osteoporosis range; this can 
best be achieved by referral to specialist centres for on-going management
It is also recommended that further research is a key priority to:
10. Link FRAX-derived risk with actual fracture occurrence in this population.
11. Examine the effects of newer systemic therapies (including anti-androgens) for prostate cancer on the skeleton 
and fracture, particularly in the metastatic setting.
12.  Monitor implementation of these guidelines in standard prostate cancer practice. 
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735 Table 1: Randomised studies of the effect of bisphosphonates and denosumab in men 
736 receiving ADT for Prostate Cancer
737 In the above studies, significant reductions in BTMs were observed following administration of bone targeted 
738 agents  Abbreviations: PC: prostate cancer; BM: bone metastasis; MAB: maximum androgen blockade; ADT: 
739 androgen deprivation; LS: lumbar spine; BMD: bone mineral density; OP: osteoporosis.
740
Year Study population N Study groups Follow-
up
Key findings
200156 Locally advanced or 
recurrent PC
47 Pamidronate + 
ADT vs ADT only
48 
weeks
No significant BMD change in pamidronate group
Significant loss of BMD at LS and hip in ADT only group 
(-3.3% and -1.8%, p<0.001)
200157 Metastatic PC 21 MAB + 
pamidronate vs 
MAB
12 
months
Significant increase in LS (+7.8% vs -5.7% p=0.0001) and 
femoral neck (+2.0% vs -2.3% p=0.0007) BMD in 
pamidronate group compared to MAB group 
200358 Non-metastatic  PC 106 Zoledronic acid 
+ ADT vs ADT
12 
months
Zoledronic acid associated with increased LS BMD 
compared to ADT alone (5.6% Vs -2.2%, p<0.001)
200559 Locally advanced PC, 
OP at baseline
60 MAB vs MAB +  
neridronic acid  
vs bicalutamide 
vs bicalutamide 
+  neridronic 
acid
12 
months
MAB group experienced significant BMD loss at LS and 
hip (-4.9% and -1.9%; p=0.002 and 0.004 respectively)
No BMD change in the MAB and neridronic acid group
Non-significant BMD loss in bicalutamide group
BMD increase at LS  (+2.5%; p<0.05) and hip (+1.6%; 
p<0.05) in bicalutamide +  neridronic acid  group
200660 Non metastatic PC 
and received ADT      
< 12 months
120 Zoledronic acid  
+ ADT vs 
placebo + ADT
12 
months
Increase in LS and hip BMD in zoledronic acid group 
compared with placebo (p<0.0001 for both)
200761 Localised and 
metastatic PC 
receiving ADT <12 
months
42 Zoledronic acid  
+ ADT vs 
placebo + ADT
12 
months
Increase in LS (+4.9% vs -2.2% p<0.0001) and femoral 
neck (0.9% vs -3.2% p<0.0001) BMD in zoledronic acid  
group compared with placebo 
2007/8 
62,63
Non-metastatic  PC 112 Alendronic acid 
+ ADT vs
placebo + ADT
(crossover at 12 
months)
24 
months
BMD increased at LS and hip with alendronic acid, and 
decreased with placebo (p<0.001) at 1 year
At crossover, significant LS and hip BMD gains continued 
during second year of alendronic acid. 
BMD maintained at hip and spine in those who switched 
to placebo,  but BMD loss at radius.
200764 Non-metastatic PC 
receiving ADT
44 Zoledronic acid  
+ ADT vs 
placebo + ADT
12 
months
Increase in hip (+4.0% vs -3.1% p<0.001) and LS (+0.7% 
vs -1.9% p=0.004) BMD with zoledronic acid compared 
with placebo  
200965 Non metastatic PC 
initiating or already 
receiving ADT
93 Zoledronic acid  
+ ADT vs 
placebo + ADT
12 
months
Increased LS BMD with zoledronic acid in those 
receiving ADT for <1year (+5.12% vs -3.13% with 
placebo, p=0.0029) and in those receiving ADT for more 
than 2 years (+4.82% vs +0.99% with placebo, p=0.0013)
200966 Non metastatic PC 1468 Denosumab + 
ADT vs placebo 
+ ADT
2 years Significant increase in LS BMD by 5.6% in denosumab 
arm vs 1.0% reduction in placebo arm (p<0.001). 
Denosumab reduced new vertebral fractures (1% vs 
3.9%) and significantly reduced BTM levels vs placebo
201167 ADT in patients with 
PC and osteoporosis
234 Denosumab + 
ADT vs 
alendronic acid  
+ADT
2 years Denosumab was superior to alendronic acid in 
improvement of LS BMD (+5.6% vs +1.1%).
201368 ADT for 2-3 years 
and OP 
104 Risedronate + 
ADT vs  placebo 
+ ADT
2 years Decreased LS BMD in both groups, no significant 
difference between groups
201369 Localised PC 186 Alendronic acid 
+ ADT vs 
placebo + ADT
12 
months
Significant increase in LS BMD with alendronic acid  
(+1.7% and -1.9% with placebo, p<0.0001)
